EBCC-I 2020 - 12th European Breast Cancer Conference (Virtual Meeting)
Oct 02 - Oct 03, 2020 | BarcelonaSpain
LARVOL is not affiliated with 12th European Breast Cancer Conference (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 18 abstracts linked to Trials
[VIRTUAL] Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial
[VIRTUAL] A Randomised Controlled Trial (RCT) of 3-dimensional simulation of the aesthetic outcome of Breast Conserving Treatment (BCT)
[VIRTUAL] Use of an Alfa-lipoic, Methylsulfonylmethane, Boswellia Serrata and Bromelain Dietary Supplement for Aromatase Inhibitors-related Arthralgia Management (AIA): a prospective phase II trial (NCT04161833)
[VIRTUAL] HLX02, a China-manufactured Trastuzumab Biosimilar Versus EU-sourced Trastuzumab: Results of a Global Phase 3, Randomized, Double-blind Efficacy and Safety Comparative Study in Metastatic Breast Cancer
[VIRTUAL] Mesh-Pocket supported prepectoral implant-based breast reconstruction: Final results of a retrospective analysis
[VIRTUAL] Real-life use of 21-gene signature: A retrospective analysis of 46 cases from private practice
[VIRTUAL] Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system
[VIRTUAL] The effect of a decision aid for breast cancer patients deciding on their radiation treatment
[VIRTUAL] Use of oral complementary-alternative medicine (OCAM) and fatigue among early breast cancer (BC) patients (pts)
[VIRTUAL] Mesh-Pocket supported prepectoral implant-based breast reconstruction: Final results of a retrospective analysis
[VIRTUAL] Use of an Alfa-lipoic, Methylsulfonylmethane, Boswellia Serrata and Bromelain Dietary Supplement for Aromatase Inhibitors-related Arthralgia Management (AIA): a prospective phase II trial (NCT04161833)
[VIRTUAL] Real-life use of 21-gene signature: A retrospective analysis of 46 cases from private practice
[VIRTUAL] HLX02, a China-manufactured Trastuzumab Biosimilar Versus EU-sourced Trastuzumab: Results of a Global Phase 3, Randomized, Double-blind Efficacy and Safety Comparative Study in Metastatic Breast Cancer
[VIRTUAL] Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system
[VIRTUAL] The effect of a decision aid for breast cancer patients deciding on their radiation treatment